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Elastic ﬁber formation involves the secretion of tropoelastin which is converted to insoluble elastin by cross-
linking, initiated by the oxidative deamination of lysine residues by lysyl oxidase. Five lysyl oxidase genes have
been discovered. This study deals with the expression of two isoforms, LOX and LOX-like (LOXL), in human
foreskin and in a human skin-equivalent (SE) model that allows the formation of elastic ﬁbers. In this model,
keratinocytes are added to a dermal equivalent made of ﬁbroblasts grown on a chitosan-cross-linked collagen-GAG
matrix. LOX and LOXL were detected by immunohistochemistry in the dermis and the epidermis of both normal
skin and in a SE. This expression was conﬁrmed by in situ hybridization on the SE. LOX and LOXL expression
patterns were conﬁrmed in human skin. The ultrastructural localization of LOXL was indicative of its association
with elastin-positive materials within the SE and human skin, though interaction with collagen could not be
discarded. LOX was found on collagen ﬁbers and could be associated with elastin-positive materials in the SE and
human skin. LOXL and LOX were detected in keratinocytes where LOX was mainly expressed by differentiating
keratinocytes, in contrast to LOXL that can be found in both proliferating and differentiating ﬁbroblasts. These data
favor a role for LOXL in elastic ﬁber formation, together with LOX, and within the epidermis where both enzymes
should play a role in post-translational modiﬁcation of yet unknown substrates.
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The skin is a complex organ composed of two main tissues:
epidermis and dermis. The epidermis, a pluri-stratified and
differentiated epithelium, is responsible for the barrier
function. The dermis, a connective tissue in which cells
are embedded in their own and abundant extracellular
matrix (ECM), is mainly composed of collagen and many
macromolecules such as elastin. Elastic fibers are respon-
sible for skin elasticity (Gibson et al, 1989), and collagen
fibers for its tensile strength. While collagen fibers can be
synthesized throughout life, elastic fibers are synthesized
mainly during development and growth, by smooth muscle
cells in blood vessels and by fibroblasts in skin (Vrhovski
and Weiss, 1998). The progressive disorganization of elastic
fibers and their replacement by collagen fibers are major
manifestations of skin aging. Otherwise, burns or deep
wounds result in scarring with loss of elasticity.
Elastic fibers, in contrast to collagen fibers, do not
spontaneously assemble. The elastic fiber consists of two
distinct components: elastin and fibrillin-rich microfibrils.
Elastin is synthesized as a 70 kDa monomer precursor that
is secreted through a trans-Golgi pathway (Davis and
Mecham, 1998). Elastogenesis is controlled by the 67 kDa
elastin binding protein that acts as a recycling chaperone
and may bring the tropoelastin molecule to the microfibrillar
scaffold (Hinek and Rabinovitch, 1994; Hinek et al, 1995).
Recently, fibulin-5 has been reported to act as a scaffold
protein at the surface of elastic fibers and to organize and
link elastic fibers to cells (Nakamura et al, 2002; Yanagisawa
et al, 2002). Interaction of tropoelastin with microfibrils
occurs via the amino-terminal domains of fibrillins 1 and 2,
and is mediated by ionic interactions involving non-oxidized
lysine side chains of tropoelastin (Trask et al, 2000; Jensen
et al, 2001). The C-terminal domain of tropoelastin is
necessary for correct orientation and subsequent cross-
linking (Vrhovski and Weiss, 1998; Robb et al, 1999), while
local exposure to matrix glycosaminoglycans may favor
tropoelastin deposition (Wu et al, 1999). Microfibril binding
is thought to contribute to the alignment of tropoelastin
molecules, thus bringing together each cluster of four
positively charged lysine side chains necessary for cross-
linking (Bedell-Hogan et al, 1993). The initial step of the
cross-linking reaction, which renders tropoelastin insoluble,
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is an oxidative deamination of lysine residues by lysyl
oxidase to produce allysine, also known as a-amino adipic
d-semialdehyde. All subsequent reactions are spontaneous
and involve the condensation of closely positioned lysine
and allysine residues to produce a variety of intra- and
intermolecular cross-links, some unique to elastin (Reiser
et al, 1992; Vrhovski and Weiss, 1998).
Lysyl oxidases have been originally described as
catalysts of the oxidative deamination of the e-amino group
of lysyl and hydroxylysyl residues of collagen and of the
lysyl residues of elastin (Kagan and Li, 2003). Over the last
few years, five genes (LOX, LOXL, LOR/LOXL2, LOR2/
LOXL3, and LOXC/LOXL4) encoding putative lysyl oxidase
isoforms have been identified (Csiszar, 2001). Their specific
roles are yet unknown. LOX, LOXL, and LOXL4 have been
shown to display enzymatic activities in vitro, using both
collagen and tropoelastin as substrates. The 50 kDa
glycosylated LOX precursor requires a maturation by the
procollagen-C-terminal proteinase (PCP) to be processed
as a 32 kDa active enzyme (Trackman et al, 1992; Cronshaw
et al, 1995). A 56 kDa LOXL precursor has been recently
isolated from bovine aorta. It can be cleaved in vitro by PCP,
leading to a fraction active on both tropoelastin and
collagen (Borel et al, 2001). The 82 kDa LOXL4 precursor
has been reported to display enzymatic activity without
activation (Ito et al, 2001). The relation at the tissue and cell
levels between LOX, LOXL, collagens, and elastin has
hardly been addressed however. The relationship between
LOX and collagen cross-linking has been demonstrated in
fibroblasts overexpressing the recombinant LOX (Seve et al,
2002). This observation has been confirmed in null homo-
zygote LOX / mice that display less collagen cross-
linking. These LOX / mice, however, also display a 60%
decrease in elastin cross-linking, as judged by the desmo-
sine residual level (Hornstra et al, 2003). This suggests both
an involvement of LOX in elastin cross-linking and the
existence of other enzymes responsible for the residual
elastin cross-linking activity. As the LOXL gene products
have been reported to be associated with the ECM in
tissues, LOXL is one candidate for this elastin cross-linking
activity (Decitre et al, 1998; Kim et al, 1999).
The aim of this study was therefore to determine whether
LOXL is expressed in a skin-equivalent (SE) model allowing
the neosynthesis and maturation of collagen and elastic
fibers (Duplan-Perrat et al, 2000). This SE is composed of a
dermal equivalent made of fibroblasts seeded in a porous
dermal substrate (collagen, glycosaminoglycans, and chit-
osan; Collombel et al, 1989), on top of which are further
seeded keratinocytes. The epidermization induces elastin
expression and the formation of typical structures of an
elastic network in the dermis, with elastin deposition on the
microfibrillar scaffold after long-term culture (Duplan-Perrat
et al, 2000). By comparison however with other skin models
where amorphous elastin has not been detected (Fleisch-
majer et al, 1993), it is known that the presence of
keratinocytes is not sufficient to trigger elastin deposition
on microfibrils. This suggests that other regulatory mecha-
nisms should occur, such as the influence of the composi-
tion of the three-dimensional scaffold and of other regulators
of the elastic fibers synthesis. The present investigation was
then performed to gain a better understanding of the key
lysyl oxidase isoform(s) that govern the synthesis and
correct assembly of elastic fibers in the SE. This model
allows for continuous assessment of elastic tissue formation
and deposition that is impossible in the human skin.
Results
Immunodetection of LOXL and LOX in the SE The initial
detection of LOXL was achieved using the anti-LOXL231–368
antibody, used to identify the precursor form of tissue LOXL
(Decitre et al, 1998; Borel et al, 2001). LOXL could be
detected using this anti-LOXL antibody at various levels of
the dermis and epidermis of SEs, at different times of
culture (Fig 1a, c, e). On day 16, 2 d after keratinocyte
seeding, LOXL was detected in fibroblasts in the dermal
part of the SE and mostly just beneath the dermo-epidermal
junction (DEJ), where the expression pattern is concen-
trated as local spots as exemplified in Fig 1a. On day 35 (Fig
1c), LOXL was detected beneath the DEJ. Deeper in the
dermis, LOXL was associated with ECM neosynthesis
where the porous structure was in the process of being
filled. LOXL staining was intense in all the dermis on day 45
(Fig 1e). On day 35, LOXL immunolabelling was observed
for all epidermal layers, with a more intense staining
beneath the DEJ. This staining expanded throughout the
epidermis by day 45. LOXL detection was eliminated by
incubation of the anti-LOXL antibody with the specific GST-
LOXL231–368 peptide prior to the immunodetection (Fig 1g).
To confirm our data, the laboratory developed a new
anti-LOXL antibody, against the residues 355–416, which
recognizes the smallest maturation product obtained by
PCP cleavage of the human LOXL precursor at the S337–
D338 bond (equivalent to the S354–D355 bond described on
bovine LOXL; Borel et al, 2001). As this region shares about
56% of similarity with the corresponding human LOX region
(in contrast to the 7% with the region 231–238), we checked
its specificity using recombinant human LOX and LOXL
expressed in HeLa cells. The anti-LOXL355–416 antibody
reacted strongly with the recombinant LOXL precursor of
about 69 kDa, while it did not react with the recombinant
56 kDa LOX precursor (Fig 2). In such conditions, the anti-
LOX228–279 antibody reacted with the 56 kDa recombinant
LOX precursor and gave no reaction with the 69 kDa LOXL
precursor (Fig 2). The pattern of immunostaining using the
new anti-LOXL antibody was similar, though lighter, to the
one obtained using the anti-LOXL231–368 antibody, with a
labelling of the dermis and the epidermis on day 45 (Fig 1i ).
As found with LOXL, LOX was detected both in the
epidermis and in the dermis of SE and normal skin (Fig 1b,
d, f ). In the SE dermis, on day 16, LOX was detected in
association with ECM (Fig 1b), with a higher and continuous
staining in the upper part of the dermis and beneath the
forming DEJ. On day 35, LOX was observed throughout the
dermis, though labelling was weak beneath the DEJ (Fig 1d ).
On day 45, the staining was intense in the deep region of the
DS, while staining under the DEJ remained weak (Fig 1f ). In
the epidermis, on day 16 the single layer of keratinocytes
seeded on the dermal layer was unlabelled (Fig 1b ). On
day 35, LOX labelling of the SE mainly concerned
the suprabasal layers, especially the spinous layers, while the
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labelling of the basal layer remained weaker (Fig 1d). On day
45, LOX epidermal staining was restricted to the basal and
spinous layers (Fig 1f ), displaying a difference in expression
pattern with LOXL. LOX staining decorated the periphery of
keratinocytes and formed a framework around juxtaposed
cells. Labelling was eliminated by a competition with the
corresponding GST-LOX peptide (Fig 1h).
Immunodetection of LOXL and LOX in human skin In
order to determine whether the positive expression of LOXL
and LOX in the SE could be correlated to human tissues,
different samples of human skin were analysed. Here,
observations made on the foreskin were shown (Fig 1). The
immunodetection of LOXL within the epidermal layer of SE
was confirmed in human foreskin (Fig 1k). It was also
observed at the same location in skin samples from the
neck or the breast (data not shown). The staining could be
pericellular and cytoplasmic. LOXL staining was low in the
dermis and stronger around blood vessels (Fig 1k). LOX was
weakly detected in the whole dermis of these different
skins, together with an intense detection within the basal
and suprabasal layers of the epidermis (Fig 1l ).
LOXL and LOX gene expression in the SE and in
keratinocytes To further confirm LOX and LOXL expres-
sion by keratinocytes, their gene expression was analyzed
by RT-PCR. Preliminary data were obtained on cells from
the separated dermis and epidermis of SE obtained after 45
d of growth, once the basement membrane is built. The
amplification of LOXL and LOX PCR products indicated that
keratinocytes could express both genes (data not shown). A
low amount of collagen mRNA was detected however,
indicating a low amount of contamination by fibroblasts. We
therefore performed RT-PCR on keratinocytes grown on a
monolayer without a feeder layer. LOX expression was not
significantly detected in undifferentiated keratinocytes (Fig
3). Its detection increased in differentiated keratinocytes
positive for Keratin K10. In contrast, LOXL was expressed in
both non-differentiated and differentiated keratinocytes.
The slight amplification of collagen I should be due to the
residual fibroblasts from the original feeder layer. This
contamination was reduced after different cell passages in
defined medium, as in differentiated keratinocytes where
LOX amplification increased.
Figure 1
Immunohistological detection of LOXL and LOX in skin equivalents
(SE) and human foreskin. LOXL immunodetection (a, c, e, g, i ) on day
16 2 d after keratinocytes seeding (a), day 35 (c), and day 45
(e, i ) using the anti-LOXL231–368 (a, c, e), the anti-LOXL231–368 antibody
adsorbed with the corresponding GST-LOXL231–368 peptide prior to the
immunodetection (g), and the new anti-LOXL355–416 (i ). LOX immuno-
detection (b, d, f, h) on day16 (b), day 35 (d ), and day 45 (f ) using the
anti-LOX228–279 (b, d, f ) or the anti-LOX228–279 antibody adsorbed with
the corresponding GST-LOX228–279 peptide prior the immunodetection
(h). A control without the first antibody displayed no staining ( j ).
Immunodetection in human foreskin using anti-LOXL231–368 (k) and anti-
LOX228–279 (l ) antibodies. The immunolabelling is indicated by a brown
deposition and the counterstaining gives the tissue its blue color. The
chitosan-cross-linked collagen-GAG matrix appears in blue. Scale bar:
.50 mm.
Figure2
Verification of antibody specificity against LOX and LOXL human
recombinant proteins. Hela cells were transfected using pcLOXL-His
(1, 3, 5) or pcLOX-His (2, 4, 6), and their cell layers were harvested 48 h
post-transfection. Cell layer proteins were analyzed on 10% SDS PAGE
and immunodetected by western blotting using the new anti-LOXL355–
416 (lanes 1 and 2), anti-LOX228–279 (lanes 3 and 4) antibodies, and the
anti-V5 antibody (lanes 5 and 6). The migration of the protein markers is
indicated with their respective molecular masses (in kDa).
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We performed in situ hybridization to confirm and locate
LOXL or LOX gene expression on the SE (Fig 4). On day 16,
LOX and COL1A1 mRNAs could be detected in the dermis
(beneath the keratinocytes) by in situ hybridization, while at
the same time LOXL and tropoelastin (TE) mRNAs were
almost not detected (data not shown). On day 35,
expression of both LOXL and LOX genes was observed
(Fig 4a and b). The LOXL gene was expressed by fibroblasts
in the dermis and by keratinocytes throughout the epidermis
(Fig 4a). The LOX gene was intensively expressed by
fibroblasts colonizing the DS (Fig 4b). Suprabasal keratino-
cytes displayed strong labelling for LOX whereas basal cells
appeared not stained. Interestingly, the expression of the
elastin gene, which was positive as expected in fibroblasts
of the dermis, was also observed, though weakly, through-
out the epidermis (Fig 4c). In contrast, the expression of
COL1A1 gene (as a control) was restricted to the dermis of
the SE (Fig 4d ).
These experiments demonstrated the expression of both
LOX and LOXL genes by keratinocytes and confirmed their
differential expression pattern. LOXL was expressed by
proliferating and non-differentiated keratinocytes, both in
monolayer culture and in the basal layer of the epidermis on
days 35 or 45. LOXL was also expressed by differentiated
keratinocytes and in the suprabasal cells of the epidermis.
In contrast, the LOX gene was not or weakly expressed
in proliferating keratinocytes (either grown in monolayer or
in the basal layer of the epidermis). LOX required the
differentiation of keratinocytes to be upregulated, either
after calcium induction of keratinocytes or within the
suprabasal layers of epidermis.
Immunoelectron microscopy To further localize LOXL and
LOX antigens in the SE, we performed immunolabelling at
the electron microscopic level. Assays were performed
on the SE on day 45, where elastin was detected as
amorphous material, associated or not with microfibrils
(Duplan-Perrat et al, 2000). Though the SE was fragile, the
immunodetection of LOXL allowed its detection throughout
the dermis in relation to the same kind of materials
responding positively to elastin immunolabelling (Fig 5a),
using both anti-LOXL antibodies (Fig 5b and c). The gold
particles could also be localized, though more rarely, in
regions rich in collagen fibers, using both anti-LOXL anti-
bodies as exemplified with the anti-LOXL355–416 (Fig 5c).
The immunolabelling of LOX allowed its detection in the
dermis, close to collagen fibers and to microfibrils without
suggesting any preferences (Fig 5d ).
In order to confirm the relation of LOXL with elastin-
positive materials, its detection was performed on normal
human skin, with foreskin tissues, less fragile and therefore
Figure 3
RT-PCR analysis of LOX and LOXL gene expression in fibroblasts
and keratinocytes. RT-PCR was performed for LOXL, LOX, a1ColI,
Keratin K10, and GAPDH on mRNA extracted from fibroblasts (F),
undifferentiated keratinocytes (Ku), and differentiated keratinocytes
(Kd).
Figure 4
LOXL (a), LOX (b), elastin (c), and a1(I ) collagen mRNAs (d ) expression in SE on day 35. In situ hybridization was performed using Dig-labelled
double-stranded DNA probes on paraffin-embedded sections. (a) LOXL mRNA expression is detected in the whole dermis and throughout the
epidermis. (b) LOX mRNA expression is mainly observed in the deep dermis. In the epidermis, cells of the basal layer are negative for LOX gene
expression, while the spinous and granulous layer cells are strongly positive. (c) Elastin mRNA is found in association with dermal fibroblasts and
within the epidermis. (d ) COL1A1 gene expression is detected in the dermis and not in the epidermis. (e) Control without probe. The DEJ position is
indicated by arrows.
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more adequate to perform double immunostaining (Fig 6a).
The anti-LOXL231–368 and anti-elastin antibodies were able
to recognize the amorphous materials, characteristic of
elastic fibers, and the microfibrils (Fig 6b). The labelling
using the anti-LOXL231–368 antibody was mainly observed at
the periphery of the elastic fibers. As for the SE, staining of
the collagen fibers using the anti-LOXL231–368 antibody
was rare (Fig 6b). LOX was immunodetected in relation
to microfibrils or to elastic fibers deposits (Fig 6c), but in
contrast to LOXL, LOX could also be found in association
with collagen fibers (Fig 6d ).
Discussion
This study was performed to examine one paradigm of
elastic and collagen fiber synthesis, i.e. the initiation of the
cross-linking reaction by lysyl oxidases, in a SE model that
allows the synthesis of both kinds of fibers (Duplan-Perrat
et al, 2000). The SE thus provides a unique model to study
this elastogenesis process, in contrast to the skin. The lysyl
oxidases form a growing family of five enzymes (Csiszar,
2001). The role of these enzymes in tissues is yet largely
unknown. Using enzymatic assays performed in vitro, the
recombinant LOX, the 56 kDa LOXL precursor from bovine
aorta activated by PCP, and the 82 kDa LOXL4 precursor
have been described to use collagen and tropoelastin as
substrates (Wang et al, 1996; Borel et al, 2001; Ito et al,
2001). Recent studies suggested an involvement of LOX in
collagen and elastin cross-linking in cells and tissues (Seve
et al, 2002; Hornstra et al, 2003; Kozel et al, 2003). Here, this
work describes the behavior of LOXL and LOX during the
development of the SE in order to address the question of
their respective role in collagen and elastin cross-linking.
In the dermis, immunohistological and in situ hybridiza-
tion analyses show that both LOXL and LOX are expressed.
LOX expression can be observed on day 16, together with
collagen I, 1 d after the addition of keratinocytes. It should
be noted that both proteins are already expressed prior to
keratinocytes seeding (data not shown). In contrast, on day
16, LOXL and elastin are rarely observed. On day 35, LOXL
is localized beneath the DEJ where LOX is nearly absent.
On day 45, we still note an expression of LOXL, LOX,
elastin, and collagen in the dermis. LOX is also found in the
deep dermis, a location that might correspond to the
transient expression at the front of ECM neosynthesis
already described for LOX (Sommer et al, 1993). The
ultrastructural localization of LOXL within the dermis of the
SE as well as the time course of its expression suggest its
proximity to elastin-positive dense deposits and to micro-
fibrils and its functional relation to the elastic tissue,
respectively. This is confirmed within human skin, where
Figure 5
(a–d). Elastin, LOXL, and LOX immunodetection by electron microscopy in the dermal part of the SE on day 45. Elastin was detected in
association with dense deposits or microfibrils (a). LOXL was also detected with such dense deposits or microfibrils positive for elastin, using anti-
LOXL355–416 (b) and the anti-LOXL231–368 (c). LOXL could be, though rarely, associated with collagen fibers as exemplified here (c). LOX labelling
could be found with dense deposits, microfibrils and with collagen (d). Negative control without primary antibody in the dermis (e). e, elastin-positive
material; m, microfibrils; c, collagen fibers. Scale bar: 200 nm.
LYSYL OXIDASES IN A SKIN EQUIVALENT 625122 : 3 MARCH 2004
LOXL antibody labels the periphery of elastic fibers, rather
than collagen fibers. The ultrastructural immunodetection of
LOX is related both to collagen and elastic fibers of the SE
and the human skin.
A putative privileged association of lysyl oxidase iso-
forms toward collagen or elastic fibers should be viewed in
the light of divergent reports that have previously addressed
this question. Using antibodies against a 32 kDa lysyl
oxidase isolated from bovine aorta, which contains sepa-
rable protein isoforms (Kagan et al, 1979; Williams and
Kagan, 1985), Kagan et al (1986) have been able to localize
the enzyme at the interface between amorphous elastic
fibers and the surrounding microfibrils in aortic tissues,
while no reaction was obtained on collagen fibers. Using
Figure 6
Double immunodetection of LOXL, LOX and elastin by electron microscopy in the dermal part of human foreskin. (a, b) Double labelling with
anti-LOXL231–368 antibody (10 nm) and anti-elastin antibody (20 nm). LOXL was detected in association with microfibrils and around elastic fibers,
not in association with the amorphous elastin-positive material spreading on microfibrils but mainly at their periphery, and rarely with collagen fibers.
(c) Double labelling with anti-LOX antibodies (10 nm) and anti-elastin antibodies (20 nm) allowed one to detect LOX with elastin-positive fibers (c).
LOX could also be detected on collagen fibers, shown here below the DEJ (d, e). The labelling corresponds to gold particles which appear as black
dots of 10 and 20 nm. m, microfibrils; c, collagen fibers; e, amorphous elastin. Scale bar: 200 nm.
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antibodies against the 32 kDa protein isolated from
placenta, Pasquali-Ronchetti and coworkers stained col-
lagen fibers of human skin, but they did not find a specific
localization on or adjacent to elastin and microfibrils
(Baccarani-Contri et al, 1989). As discussed by these latter
authors, this discrepancy might reflect the different speci-
ficity of the antibodies toward lysyl oxidase isoforms or the
presence of masking proteins, such as proteoglycans
(Baccarani-Contri et al, 1989; Quaglino et al, 1993). Our
data, using specific antibodies against LOX and LOXL, are
in favor of a relation between LOX and both collagen and
elastic fibers, and between LOXL and elastic fibers,
respectively, while the relation between LOXL and collagen
cannot be discarded. The relation between LOX and
collagen has already been reported (Seve et al, 2002). Co-
regulation of LOX and collagen I has been described in the
schistosomiasis liver fibrosis model, and a DNA sequence,
LOcol1, found in the promoters of the LOX, a1(I) and a2(I)
collagen genes, regulates the LOX promoter (Sommer et al,
1993; Jourdan-Le Saux et al, 1997). On the other hand,
upregulation of LOXL expression precedes collagen I and
LOX expression in the schistosomiasis and in the CCl4-
induced hepatic fibrosis models (Decitre et al, 1998; Kim
et al, 1999). In both cases, LOXL expression coincides with
collagen III expression, though the relation with elastin has
not been addressed. Accordingly, if the relation between
LOX and collagen I fibers has been conclusively established
at the promoter, protein, cell, and tissue levels, the question
remained open for the relation of LOX, LOXL, and elastic
fiber components. Our data suggest that both LOX and
LOXL can be present on elastic fibers, though further work
is required to study their interaction and their regulation
during the formation and aging of elastic fibers. On the other
hand, it also remains to clarify which lysyl oxidase isoform
is responsible for collagen IV cross-linking, knowing that
inhibition of lysyl oxidase activity by b-aminoproprionitrile
(b-APN), a specific inhibitor of lysyl oxidase activity (Smith-
Mungo and Kagan, 1998), interferes with the formation of
the basement membrane of the SE (Noblesse et al,
unpublished data). The use of the SE described here could
be useful to answer these questions.
One intriguing finding in this study is the observation of
LOX and LOXL within the epidermis. The expression of LOX
by human keratinocytes has already been documented
(Wakasaki and Ooshima, 1990; Kobayashi et al, 1994). The
exact location of LOX and LOXL within the epidermis could
not be determined by immunoelectron microscopy, as a
diffuse concentration of gold labels was observed in the
cytoplasm of keratinocytes and between the keratinocytes,
in association with amorphous structures (data not shown).
Incidentally, we observed that neither LOX nor LOXL is
associated with desmosome junctions, which are essen-
tially unlabelled. The substrates of LOX and LOXL could be
one of the numerous proteins that fill the space between
keratinocytes, or intracellular proteins involved in cell
signalling. Collagens, the main classical substrates of LO,
are not yet known to be present in the epidermis, except
type XIII collagen (Peltonen et al, 1999). Although collagen
XIII can be found between keratinocytes however, its main
localization is between the basal layer of keratinocytes and
the basement membrane, where neither LOX nor LOXL as
found in large amounts. Many other proteins of the cornified
cell envelope, including involucrin, small proline-rich pro-
teins, loricrin and filaggrin, are known to be substrates for
transglutaminases (Aeschlimann and Thomazy, 2000), but
the localization of LOX and LOXL suggests that some of
them might also be cross-linked by lysyl oxidase isoforms.
Another candidate substrate for LOX or LOXL between
keratinocytes might be elastin. Different reports have
described the expression of elastin and microfibril mRNAs
in keratinocytes (Haynes et al, 1997; Kajiya et al, 1997).
Interestingly, it has been reported that elastin mRNA
expression is increased after UV exposure in the epidermal
layers (Seo et al, 2001). No data however have been
presented on the role of elastin as an epidermal cell
constituent. The observation of elastin molecule, but not
necessarily elastic fibers, within the epidermis of the SE and
other reports in the skin (Haynes et al, 1997; Kajiya et al,
1997; Seo et al, 2001) lead to future studies where it will be
interesting to determine whether or not elastin can be
deposited in normal human epidermis. In this regard, it is
interesting to note that elastin peptides have been reported
to influence the keratinocyte migration and differentiation
(Fujimoto et al, 2000a, b).
The putative existence of LOX substrates within or
outside the cell might be related to yet unexplained features
of this enzyme, first discovered as a tumor suppressor gene
and also using the basic fibroblast growth factor as
substrate (Contente et al, 1990; Kenyon et al, 1991; Li et al,
2003). Deregulation of LOX, by expressing an antisense
LOX cDNA in fibroblasts, induces a loss of contact inhibition
and decreases the expression pattern of proteins involved
in cell–matrix interactions, resulting in a highly tumorigenic
phenotype (Giampuzzi et al, 2001). As LOX can regulate the
activity of NF-kB in fibroblasts (Jeay et al, 2003) and is
induced during the first stages of keratinocyte differentiation
(this study), it would be interesting to determine its role
during the NF-kB-dependent differentiation of keratinocytes
(Bell et al, 2002). The location of LOX (and LOXL) and their
yet unknown substrate(s), at the periphery of keratinocytes
or fibroblasts, would make sense in the light of a role for this
enzyme in cell–matrix or cell–cell contacts. The SE provides
a new cell model to study the mechanisms that target LOX
and LOXL to unexpected locations and will help to identify
new functions for the LO family of proteins.
Materials and Methods
Human cell cultures Keratinocytes and fibroblasts were isolated
from human foreskin. Fibroblasts were grown in Dulbecco’s
modified Eagle’s medium (DMEM with Glutamax-1, Life Technol-
ogies, Cergy Pontoise, France) supplemented with 10% fetal calf
serum (FCS) (HyClone, Logan, Utah), 20 mg per mL gentamicin
(Panpharma, Fouge`res, France), 100 IU per mL penicillin (Sarbach,
Suresnes, France), and 1 mg per mL amphotericin B (Bristol Myers
Squibb, Puteaux, France). For the SE, keratinocytes were grown
in a 3:1 mixture of DMEM and Ham’s F12 (Life Technologies),
respectively, supplemented with 10% FCS (HyClone), 10 ng per
mL epidermal growth factor (EGF) (Austral Biologic, San Ramon,
California), 0.12 IU per mL insulin (Lilly, Saint-Cloud, France), 0.4 mg
per mL hydrocortisone (UpJohn, St Quentin en Yvelines, France), 5
mg per mL triiodo-L-thyronine (Sigma, St Quentin Fallavier, France),
24.3 mg per mL adenine (Sigma), and antibiotics. For keratinocyte
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monolayer culture, cells were grown on a feeder layer of irradiated
fibroblasts, or without a feeder layer in defined K-SFM medium
(Life Technologies) supplemented or not during 5 d after con-
fluence with 1.2 mM CaCl2.
Preparation of dermal equivalent Fibroblasts from the seventh
passage were seeded at a density of 250,000 cells per cm2 onto a
dermal substrate (DS) made of chitosan-cross-linked collagen-
GAG matrix prepared as previously described (Collombel et al,
1989). This dermal equivalent was grown for 14 d at 371C in a 5%
CO2 atmosphere. The fibroblast medium was supplemented with
50 mg per mL L-ascorbic acid (Sigma) and changed every day.
Preparation of SE Keratinocytes were seeded on the dermal
equivalent on day 14, at a density of 250,000 cells per cm2
(Duplan-Perrat et al, 2000). Briefly, after 7 d of submerged culture
in the keratinocyte medium, the SE was elevated at the air–liquid
interface and cultured in a simplified keratinocyte medium contain-
ing DMEM supplemented with 10% FCS, 10 ng per mL EGF, 0.12
IU per mL insulin, 0.4 mg per mL hydrocortisone, and antibiotics.
The SE samples were harvested at 16, 35, and 45 d of culture
following fibroblasts seeding. Samples were harvested for histol-
ogy, immunohistology studies, electron microscopy, and in situ
hybridization studies.
Production and characterization of anti-LOXL antibodies The
first polyclonal rabbit anti-LOX and anti-LOXL antibodies used in
this study have been described previously (Sommer et al, 1993;
Borel et al, 2001). These rabbit anti-LOX and anti-LOXL antibodies
have been raised against the regions 222–356 of murine LOX and
231–368 of human LOXL, respectively. One new anti-LOXL anti-
body was raised against the region 355–416 of human LOXL, fused
in frame to the glutathion-S-transferase (GST). The chimerical gene
was constructed by the in-frame insertion of human LOXL cDNA at
the end of the glutathion-S-transferase (GST) gene in the BamHI-
XhoI sites of pGEX-4T-3 expression plasmid (Amersham, Orsay,
France). The GST-LOXL355–416 fusion gene was constructed by
introducing the sequence of human LOXL cDNA, generated by
PCR using the sense 50-TTGGATCCAGCGTAGGCAGCGTGTAC-30
primer, the antisense 50-AAACTCGAGCATCGTAGTCGGTGGC-30
primer, and bioTaq polymerase (Bioprobe). As control, a new anti-
LOX antibody was raised in an equivalent region, against the region
228–279 of human LOX. The GST-LOX228–279 fusion gene was
constructed by introducing the human LOX sequence amplified
using the 50-TTGGATCCGTGCAGAAGATGTCCATGTAC-30 and 50-
TTTCTCGAGGCTGGGTAAGAAATCTGATG-30 sense and antisense
primers, respectively.
The antibodies were obtained in rabbits and purified as
described (Sommer et al, 1993; Borel et al, 2001). For control
experiments, the antibodies were purified by affinity chromato-
graphy on the corresponding peptide antigen as described (Borel
et al, 2001). For the adsorption experiments, the antibodies were
incubated for 3 h at 201C with the respective GST-fusion proteins
coated on a nitrocellulose Hybond-ECL membrane (Amersham)
prior to the immunodetection test.
To check the new antibodies, the full-length LOXL fragment was
amplified by PCR from cDNA of MRC5 fibroblasts using the
Expand High Fidelity PCR System (Roche, Mey Pan, France). The
sense 50-CAGAGGATCACCATGGCTCTG-30 and antisense 50-
CGAGACAGGAGTCGACAATTTTGCAG-30 primers were used.
The amplified segment displayed one difference with the published
sequence, with a guanine in position 421 instead of a thymine
(Kenyon et al, 1993). This introduced a leucine141 to arginine141
transition, also found in all checked LOXL sequences from the
NCBI library. We therefore used this LOXL coding sequence,
introduced under the control of the CMV promoter and in frame
with a V5-His C-terminal tail. Taking advantage of the restriction
sites introduced into the PCR primers, BamHI for the forward and
HincII/SalI for the reverse (this primer eliminates also the stop
codon of LOXL), the 1744 bp PCR product was cloned into the
pBluescript II SKþ vector (Ozyme, St. Quentin, France) and
sequenced (MWG Biotech, Ebersberg, Germany). The BamHI/SalI
fragment was subcloned into the pcDNA4/V5-His type A (Invitro-
gen) expression vector using its BamHI and XhoI sites. The
resulting vector was called pcLOXL-His and was used for transient
transfection experiments. The 33 to þ 1284 LOX sequences was
inserted into pcDNA4 (Invitrogen, Cergy-Pontoise, France) as
described (Seve et al, 2002), resulting in pcLOX-His. Transient
transfections of Hela cells were performed using the Lipofectamine
reagent (Life Technologies) on pre-confluent cells. Protein expres-
sion was detected from the cell layer using the anti-LO antibodies
or using an anti-V5 antibody (Invitrogen) at a dilution of 1:100, by
western blotting as described (Decitre et al, 1998), using the
Alkaline Phosphatase Conjugate Substrate Kit (Biorad, Marne la
Coquette, France). Protein mass markers were purchased from
Biorad.
Histology and immunohistology procedures
Histology and immunohistochemistry studies The SE was fixed in
Bouin’s fixative or in 10% formalin solution (Sigma) and embedded
in paraffin. Sections (6 mm) were de-paraffinized and whitened in
glycine-HCl (100 mmol per liter). Beside the anti-LOX and anti-
LOXL antibodies, the anti-human elastin antibodies were obtained
from Sigma and Novotec (Lyon, France). The antibodies were used
at the following dilution: 1:1000 (anti-LOX222–356), 1:500 (anti-
LOXL231–368, anti-elastinNovotec), 1:100 (anti-LOXL355–416), and 1:50
(anti-elastin Sigma). The staining of elastin requires an unmasking
step using 0.2% hyaluronidase (Sigma). Peroxidase-conjugated
goat anti-rabbit IgG (DAKO, Trappes, France) was used to detect
the immunocomplexes, using diaminobenzidine as substrate
(DAKO). Counterstaining was performed using Harris’ hematoxylin.
For controls, the primary antibody was omitted. Multiple serial
sections of each specimen were processed to ensure representa-
tive samples.
Immunoelectron microscopy Tissues were fixed for 3 h at 41C with
4% paraformaldehyde in PBS containing 0.1% glutaraldehyde,
washed in phosphate buffer containing 0.4 M cacodylate-sacchar-
ose and 0.2 M lysine, dehydrated in graded ethanol solutions, and
embedded in LR White (Euromedex, Mundols, France). Post-
embedding labelling was performed using the primary antibodies
(anti-LOXL, anti-LOX, anti-elastin (Sigma)) diluted 1:50 in Tris–HCl
buffer (pH 8.2), supplemented with 1% BSA, and then with 10 nm
gold-conjugated anti-rabbit IgG or 20 nm gold-conjugated anti-
mouse IgG (Biocell, Tebu, France) diluted 1:40, respectively.
Samples were contrasted using aqueous 3% uranyl acetate and
lead citrate buffer, and then examined on a JEOL 1200 EX electron
microscope.
In situ hybridization and reverse transcriptase polymerase
chain reaction (RT-PCR) Double-stranded DNA probes were
produced using the polymerase chain reaction (PCR). The
following sense and antisense primers were used: for human
a1(I) collagen, primers 50-GTGGAGAGTACTGGATTG-30 and 50-
TCGTGCAGCCATCGACAG-30 (allowing the amplification of the
mRNA region 3812–4249); for human tropoelastin, 50-GTATATACC-
CAGGTGGCGTG-30 and 50-CGAACTTTGCTGCTGCTTTAG-30 (re-
gion 443 of 799); for human LOX, 50-GGTGGCCGACCCCTACTACA
TCC-30 and 50-GCAAATCGCCTCTGGTAGCCATAGTC-30 (region
645 of 1016); for human LOXL, 50-GACATAACCGACGTGCAGCC-
30 and 50-ATCCACGTTCGCTCCCTGAG-30 (region 1564 of 1869).
The DNA was amplified using Taq Polymerase (Promega, Char-
bonnie`res, France) and Dig-11-dUTP (Roche, Meylan, France)
as labelled nucleotide. In situ hybridization was performed on
paraffin-embedded sections, as previously described (Le Guellec
et al, 1994), with modifications. Briefly, samples were de-
paraffinized and treated using proteinase K (Roche) at 2 mg per
ml for 15 min at 201C. Endogenous peroxidases were inhibited as
indicated in the TSAþ amplification kit (NEN, Boston, Massachus-
sets). Prehybridization was performed for 2 h at 371C in 20 mM
phosphate buffer (pH 7.4), supplemented with 50% deionized
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formamide, 2  SSC, 5 mM EDTA, 2.5  Denhardt’s solution, 200
mg per mL denaturated herring sperm DNA, 1 mg per ml salmon
sperm DNA, and 10 mg per mL tRNA. Hybridization was performed
for 16 h at 371C in 20 mM phosphate buffer (pH 7.4), supplemented
with 50% deionized formamide, 2  SSC, 5 mM EDTA,
2.5  Denhardt’s solution, 200 mg per mL denaturated herring
sperm DNA, 10% dextran sulfate, with or without the probes
previously denaturated for 5 min in a boiling water bath. Following
hybridization, the slides were successively washed twice for 10
min at 201C (or 371C for collagen) in 2  SSC/50% formamide,
1  SSC/50% formamide, 1  SSC, and 0.5  SSC. After dehy-
dration, the Dig-labelled hybrids were detected using an anti-DIG
antibody conjugated to horseradish peroxidase (Roche). The final
detection of complexes was carried out using the TSAþ
amplification kit (NEN) as described by the manufacturer. Positive
signals were shown to correspond to the alkaline phosphatase
activity linked to the TSA amplification procedure, carried out for
2 h at room temperature, as judged by the precipitation of
tetrazolium salts (using NBT/BCIP as substrates).
In addition to the LOX and LOXL primers, the following primer
pairs were used for the detection of gene expression by RT-PCR on
human fibroblast and keratinocyte mRNA: for glyceraldehyde 3-
phospho-dehydrogenase (GAPDH), 50-ATCACTGCCACCCAGAA-
GAC-30 and 50- ATGAGGTCCACCACCCTGTT-30; for Keratin
K10, 50-ACCGGTGATGTGAATGTGG-30 and 50-CCTGAATCTGT-
GAGAGCTGC-30 (amplifying the 878–1208 human K10 segment);
for collagen a1(I), 50-GCCGTGACCTCAAGATGTGC-30 and 50-
GGTTTGACTTGGGGGGGTTT-30.
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